Management of patients with hereditary hypercoagulable disorders

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 169-185

  Kearon, C ^a   Crowther, M ^a   Hirsh, J ^a  

^a HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

Anticoagulation; Hypercoagulable states; Prophylaxis; Thrombophilia; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ANTICOAGULATION; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOSIS; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBINS; ESTROGEN REPLACEMENT THERAPY; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0034100330     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.169     Document Type: Review

References (84)

1. 1. Egeberg O. 1965. Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath. Haemorrh. 13:516
2. 2. Griffin JH, Evatt B, Zimmerman TS, et al. 1981. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 68:1370-73
3. 3. Comp PC, Nixon RR, Cooper MR, Esmon CT. 1984. Familial protein S deficiency is associated with recurrent thrombosis. J Clin. Invest. 74:2082-88
4. 4. Dahlback B, Carlsson M, Svensson PJ. 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: predication of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90: 1004-8
5. 5. Bertina RM, Koeleman BPC, Koster T, et al. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67
6. 6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. 1996. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-703
7. 7. Haverkate F, Samama M. 1995. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb. Haemost. 73(1):151-61
8. 8. Van den Belt AGM, Huisman MV, Hirsh J. 1996. Familial thrombophilia: a review analysis. Clin. Appl. Thromb. Hemost. 2(4):227-36
9. 9. Cattaneo M. 1999. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost. 81:165-76
10. 10. Koster T, Blann AD, Briet E. 1995. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152-55
11. 11. Rodeghiero F, Tosetto A. 1999. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann. Intern. Med. 130:643-50
12. 12. Mateo J, Oliver A, Borrell M, et al. 1997. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb. Haemost. 11: 444-51
13. 13. Leroyer C, Mercier B, Oger E, et al. 1998. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb. Haemost. 80:49-51
14. 14. Simioni P, Sanson BJ, Prandoni P, et al. 1999. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb. Haemost. 81:198-202
15. 15. Lane DA, Mannucci PM, Bauer KA, et al. 1996. Inherited thrombophilia: part 2. Thromb. Haemost. 76(6):824-34
16. 16. Lane DA, Mannucci PM, Bauer KA, et al. 1996. Inherited thrombophilia: part 1. Thromb Haemost. 76 (5):651-62
17. 17. Lane DA, Olds RJ, Boisclair M, et al. 1993. Antithrombin III mutation database: first update. Thromb. Haemost. 70:361-69
18. 18. Tait RC, Walker ID, Perry DJ, et al. 1994. Prevalence of antithrombin deficiency in the healthy population. Br. J. Haematol. 87:106-12
19. 19. Meade TW, Dyer S, Howarth DJ. 1990. Antithrombin III and procoagulant activity: sex differences and effects of the menopause, Br. J. Haematol. 74:77-81
20. 20. Finazzi G, Caccia R, Barbui T. 1987. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb. Haemost. 58:1094
21. 21. Miletich JP. 1998. Thrombophilia as a multigenic disorder. Semin. Thromb. Haemost. 24:13-20
22. 22. Hirsh J, Piovella F. 1989. Congenital antithrombin III deficiency. Am. J. Med. 87:34-385 (Suppl.)
23. 23. Tait RC, Walker ID, Reitsma PH, et al. 1995. Prevalence of protein C deficiency in the healthy population. Thromb. Haemost. 73:87-93
24. 24. Miletich J, Sherman L, Broze G. 1987. Absence of thrombosis in subjects with heterozygous protein C deficiency. N. Engl. J. Med. 317(16):991-96
25. 25. Allaart CF, Poort SR, Rosendaal FR, et al. 1993. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 341:134-38
26. 26. Heijboer H, Brandjes PM, Buller HR, et al. 1990. Defiencies of coagulation -inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N. Engl. J. Med. 323:-1512-16
27. 27. Koster T, Rosendaal FR, Briët E, et al. 1995. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 85:2756-61
28. 28. Koster T, Rosendaal FR, de Ronde H, et al. 1993. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 342:1503-6
29. 29. Ridker PM, Hennerkens CH, Lindpainter K, et al. 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332:912-17
30. 30. Middeldorp S, Henkens CMA, Koopman MMW, et al. 1998. The incidence of venous thromboembolism in family members of patients with factor V leiden mutation and venous thrombosis. Ann. Intern. Med. 128:15-20
31. 31. Rees DC, Cox M, Clegg JB. 1995. World distribution of factor V Leiden. Lancet 346:1133-34
32. 32. Hillarp A, Zöller B, Dahlbäck B. 1996. Activated protein C resistance as a basis for venous thrombosis. Am. J. Med. 101:534-40
33. 33. Ridker PM, Miletich JP, Hennekens CH, Buring JE. 1997. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 277:1305-7
34. 34. Chan WP, Lee CK, Kwong YL, Liang R. 1998. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91:1135-39
35. 35. Mayer EL, Jacobsen DW, Robinson K. 1996. Homocysteine and coronary atherosclerosis. J. Am. Coll. Cardiol. 27:517-27
36. 36. Tosetto A, Missiaglia E, Gatto E, Rodeghiero F. 1997. The VITA project: phenotype resistance to activated protein C and FV Leiden mutation in the general population. Thromb. Haemost. 78:859-63
37. 37. Leroyer C, Mercier B, Escoffe M, et al. 1997. Factor V Leiden prevalence in venous thromboembolism patients. Chest 111:1603-6
38. 38. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. 1995. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85(6):1504-8
39. 39. Vandenbroucke JP, Koster T, Briet E, et al. 1994. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453-57
40. 40. Martinelli I, Sacchi E, Landi G, et al. 1998. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N. Engl. J. Med. 338:1793-97
41. 41. McColl MD, Ramsay JE, Tait RC, et al. 1997. Risk factors for pregnancy associated venous thromboembolism. Thromb. Haemost. 78:1183-88
42. 42. Bokarewa MI, Bremme K, Blomback M. 1996. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br. J. Haematol. 92:473-78
43. 43. Ridker PM, Hennekens CH, Seihub J, et al. 1997. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95:1777-82
44. 44. Cattaneo M, Tsai MY, Bucciarelli P, et al. 1997. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arteriosder. Thromb. Vasc. Biol. 17:1662-66
45. 45. Margaglione M, D'Andrea G, d'Addedda M, et al. 1998. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV leiden and the prothrombin A20210 mutation, Thromb. Haemost. 79:907-11
46. 46. Gandrille S, Greengard JS, Alhenc-Gelas M, et al. 1995. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 86:219-24
47. 47. Zoller B, Holm J, Svensson P, Dahlback B. 1996. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gin mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb. Haemost. 75:270-74
48. 48. Van Boven HH, Reitsma PH, Rosendaal FR, et al. 1996. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb. Haemost. 75:417-21
49. 49. Ridker PM, Robert JG, Miletich JP, et al. 1997. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann. Intern. Med. 126:528-31
50. 50. Ridker PM, Hennekens CH, Miletich JP. 1999. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation 99:999-1004
51. 51. Rosendaal FR, Doggen CJM, Zivelin A, et al. 1998. Geographic distribution of the 20210 G to a prothrombin variant. Thromb. Haemost. 79:706-8
52. 52. Margaglione M, Brancaccio V, Giuliani N, et al. 1998. Increased risk for venous thrombosis in carriers of the prothrombin G - a 20210 gene variant. Ann. Intern. Med. 129:89-93
53. 53. DeStefano V, Chiusolo P, Paciaroni K, et al. 1998. Prevalence of the factor II G20210A mutation in symptomatic patients with inherited thrombophilia. Thromb. Haemost. 80:342-43
54. 54. Makris M, Preston FE, Beauchamp NJ, et al. 1997. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb. Haemost. 78:1426-29
55. 55. Kearon C, Gent M, Hirsh J, et al. 1999. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340:901-7
56. 56. Schulman S, Granqvist S, Holmstrom M, et al. 1997. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N. Engl. J. Med. 336:393-98
57. 57. Van den Belt AGM, Sanson BJ, Simioni P, et al. 1997. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch. Intern. Med. 157:2227-32
58. 58. Schulman S, Granqvist S, Holmström M, et al. 1997. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. W. Engl. J. Med. 336:393-98
59. 59. Palareti G, Leali N, Coccheri S, et al. 1996. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Lancet 348:423-28
60. 60. Landefeld CS, Beyth RJ. 1993. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95:315-28
61. 61. Beyth RJ, Quinn LM, Landefeld S. 1998. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. 105:91-99
62. 62. Research Committee of the British Thoracic Society. 1992. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340:873-76
63. 63. Schulman S, Rhedin A-S, Lindmarker P, et al. 1995. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N. Engl. J. Med. 332:1661-65
64. 64. Levine MN, Hirsh J, Gent M, et al. 1995. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb. Haemost. 74:606-11
65. 65. Douketis JD, Kearon C, Bates S, et al. 1998. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458-62
66. 66. Clagett GP, Anderson FA, Geerts WH, et al. 1998. Prevention of venous thromboembolism. Chest 114:531-560S
67. 67. Pabinger I, Kyrle PA, Heistinger M, et al. 1994. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb. Haemost 71:441-45
68. 68. Papinger I, Schneider B. 1994. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb. Haemost. 71:548-52
69. 69. Hulley S, Grady D, Bush T, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-13
70. 70. Pini M, Aiello S, Manotti C, et al. 1994. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis. Thromb. Haemost. 72(2):191-97
71. 71. Prandoni P, Lensing AWA, Cogo A, et al. 1996. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125:1-7
72. 72. Schulman S. 1997. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb. Haemost. 78(1):693-98
73. 506→Gln mutation in the gene for factor V (factor V Leiden). N. Engl. J. Med. 336:399-403
74. 74. Ridker PM, Miletich JP, Stampfer MJ, et al. 1995. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92:2800-2
75. 75. Eichinger S, Pabinger I, Stumpften A, et al. 1997. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb. Haemost. 77(4):624-28
76. 76. Eichinger S, Minar E, Hirschl M, et al. 1999. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb. Haemost. 81:14-17
77. 77. Friederich PW, Sanson BJ, Simioni P, et al. 1996. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann. Intern. Med. 125:955-60
78. 78. Preston FE, Rosendaal FR, Walker ID, et al. 1996. Increased fetal loss in women with heritable thrombophilia. Lancet 348:913-16
79. 79. Kupferminc MJ, Eldor A, Steinman N, et al. 1999. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med. 340:9-13
80. 80. Greer IA. 1999. Thrombosis in pregnancy: maternal and fetal issues. Lancet 353:1258-65
81. 81. Conard J, Horellou MH, Van Dreden P, et al. 1990. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C, or protein S: study of 78 women. Thromb. Haemost. 63:319-30
82. 82. DeStephano V, Leone G, Mastrangelo S. 1994. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost. 71:799-800
83. 83. Lindqvist PG, Svensson PJ, Marsal K. 1999. Activated protein C resistance (FV:Q506) and pregnancy. Thromb. Haemost. 81:532-37
84. 84. Rosendaal FR. 1993. Venous thrombosis: a multicausal disease. Lancet 353: 1167-73